Table 1—

Burdens of insulin therapy as a first-line approach in type 2 diabetes

Weight gain
Hypoglycemia
Low success rate in reaching A1C targets
Nonsignificant improvement in cardiovascular outcome
No preventive effect on β-cell deterioration